News

14
Oct 2021

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
09
Sep 2021

BenevolentAI appoints Dr John Orloff to its Board of Directors

Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
09
Jul 2021

BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman

Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
05
May 2021

Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis

Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.